February 07, 2020

iVeena appoints Dr. Amir Shojaei to the iVeena Board of Directors. Dr. Shojaei was previously the Vice President and Therapeutic Area Head in Ophthalmology at Shire/Takeda.

Dr. Shojaei was the Vice President and Therapeutic Area (TA) Head in Ophthalmology at Shire/Takeda. He oversaw all aspects of clinical stage ophthalmic pipeline assets. Most recently, Amir's team brought Xiidra® (lifitegrast) from development to U.S. NDA filing and approval. Amir’s active engagement in the clinical development around design and implementation of OPUS-3, as well as the analysis of totality of evidence, were pivotal in the negotiations with the FDA leading to a US approval in July 2016 and follow on registration filings and approvals in Canada, Mexico, Australia, Switzerland, and the Gulf countries.

During his tenure at the Ophthalmics TA, Shire successfully acquired/licensed four innovative ophthalmology assets contributing to the development and growth of the franchise, aimed at improving vision-related quality of life. He helped identify strategic and viable opportunities, looking to secure and expand Shire’s global footprint and overall commitment to the eye care community.

Amir has built a career in life sciences with over 23 years of drug development experience, focused on the clinical development, registration and commercialization of biopharmaceuticals and biologics in multiple therapeutic areas.